<?xml version="1.0" encoding="UTF-8"?>
<document id="DrugDDI.d53" origId="Celecoxib"><sentence id="DrugDDI.d53.s0" origId="s0" text="General: Significant interactions may occur when celecoxib is administered together with drugs that inhibit P450 2C9."><entity id="DrugDDI.d53.s0.e0" origId="s0.p6" charOffset="49-58" type="drug" text="celecoxib"/><entity id="DrugDDI.d53.s0.e1" origId="s0.p9" charOffset="89-94" type="drug" text="drugs"/><entity id="DrugDDI.d53.s0.e2" origId="s0.p12" charOffset="108-112" type="drug" text="P450"/><pair id="DrugDDI.d53.s0.p0" e1="DrugDDI.d53.s0.e0" e2="DrugDDI.d53.s0.e1" interaction="true"/><pair id="DrugDDI.d53.s0.p1" e1="DrugDDI.d53.s0.e0" e2="DrugDDI.d53.s0.e2" interaction="false"/><pair id="DrugDDI.d53.s0.p2" e1="DrugDDI.d53.s0.e1" e2="DrugDDI.d53.s0.e2" interaction="false"/></sentence><sentence id="DrugDDI.d53.s1" origId="s1" text="Celecoxib metabolism is predominantly mediated via cytochrome P450 2C9 in the liver."><entity id="DrugDDI.d53.s1.e0" origId="s1.p13" charOffset="0-9" type="drug" text="Celecoxib"/><entity id="DrugDDI.d53.s1.e1" origId="s1.p17" charOffset="51-70" type="drug" text="cytochrome P450 2C9"/><entity id="DrugDDI.d53.s1.e2" origId="s1.p18" charOffset="78-83" type="drug" text="liver"/><pair id="DrugDDI.d53.s1.p0" e1="DrugDDI.d53.s1.e0" e2="DrugDDI.d53.s1.e1" interaction="true"/><pair id="DrugDDI.d53.s1.p1" e1="DrugDDI.d53.s1.e0" e2="DrugDDI.d53.s1.e2" interaction="false"/><pair id="DrugDDI.d53.s1.p2" e1="DrugDDI.d53.s1.e1" e2="DrugDDI.d53.s1.e2" interaction="false"/></sentence><sentence id="DrugDDI.d53.s2" origId="s2" text="Co-administration of celecoxib with drugs that are known to inhibit 2C9 should be done with caution."><entity id="DrugDDI.d53.s2.e0" origId="s2.p20" charOffset="21-30" type="drug" text="celecoxib"/><entity id="DrugDDI.d53.s2.e1" origId="s2.p21" charOffset="36-41" type="drug" text="drugs"/><pair id="DrugDDI.d53.s2.p0" e1="DrugDDI.d53.s2.e0" e2="DrugDDI.d53.s2.e1" interaction="true"/></sentence><sentence id="DrugDDI.d53.s3" origId="s3" text="In vitro studies indicate that celecoxib is not an inhibitor of cytochrome P450 2C9, 2C19 or 3A4."><entity id="DrugDDI.d53.s3.e0" origId="s3.p34" charOffset="31-40" type="drug" text="celecoxib"/><entity id="DrugDDI.d53.s3.e1" origId="s3.p37" charOffset="64-83" type="drug" text="cytochrome P450 2C9"/><pair id="DrugDDI.d53.s3.p0" e1="DrugDDI.d53.s3.e0" e2="DrugDDI.d53.s3.e1" interaction="false"/></sentence><sentence id="DrugDDI.d53.s4" origId="s4" text="In vitro studies also indicate that celecoxib, although not a substrate, is an inhibitor of cytochrome P450 2D6."><entity id="DrugDDI.d53.s4.e0" origId="s4.p45" charOffset="36-45" type="drug" text="celecoxib"/><entity id="DrugDDI.d53.s4.e1" origId="s4.p50" charOffset="92-111" type="drug" text="cytochrome P450 2D6"/><pair id="DrugDDI.d53.s4.p0" e1="DrugDDI.d53.s4.e0" e2="DrugDDI.d53.s4.e1" interaction="true"/></sentence><sentence id="DrugDDI.d53.s5" origId="s5" text="Therefore, there is a potential for an in vivo drug interaction with drugs that are metabolized by P450 2D6."><entity id="DrugDDI.d53.s5.e0" origId="s5.p56" charOffset="69-74" type="drug" text="drugs"/><entity id="DrugDDI.d53.s5.e1" origId="s5.p60" charOffset="99-108" type="drug" text="P450 2D6"/><pair id="DrugDDI.d53.s5.p0" e1="DrugDDI.d53.s5.e0" e2="DrugDDI.d53.s5.e1" interaction="false"/></sentence><sentence id="DrugDDI.d53.s6" origId="s6" text="Clinical studies with celecoxib have identified potentially significant interactions with fluconazole and lithium."><entity id="DrugDDI.d53.s6.e0" origId="s6.p62" charOffset="22-31" type="drug" text="celecoxib"/><entity id="DrugDDI.d53.s6.e1" origId="s6.p66" charOffset="90-101" type="drug" text="fluconazole"/><entity id="DrugDDI.d53.s6.e2" origId="s6.p68" charOffset="106-113" type="drug" text="lithium"/><pair id="DrugDDI.d53.s6.p0" e1="DrugDDI.d53.s6.e0" e2="DrugDDI.d53.s6.e1" interaction="true"/><pair id="DrugDDI.d53.s6.p1" e1="DrugDDI.d53.s6.e0" e2="DrugDDI.d53.s6.e2" interaction="true"/><pair id="DrugDDI.d53.s6.p2" e1="DrugDDI.d53.s6.e1" e2="DrugDDI.d53.s6.e2" interaction="false"/></sentence><sentence id="DrugDDI.d53.s7" origId="s7" text="Experience with nonsteroidal anti-inflammatory drugs (NSAIDs) suggests the potential for interactions with furosemide and ACE inhibitors."><entity id="DrugDDI.d53.s7.e0" origId="s7.p70" charOffset="16-52" type="drug" text="nonsteroidal anti-inflammatory drugs"/><entity id="DrugDDI.d53.s7.e1" origId="s7.p72" charOffset="54-60" type="drug" text="NSAIDs"/><entity id="DrugDDI.d53.s7.e2" origId="s7.p77" charOffset="107-118" type="drug" text="furosemide"/><entity id="DrugDDI.d53.s7.e3" origId="s7.p79" charOffset="122-136" type="drug" text="ACE inhibitors"/><pair id="DrugDDI.d53.s7.p0" e1="DrugDDI.d53.s7.e0" e2="DrugDDI.d53.s7.e1" interaction="false"/><pair id="DrugDDI.d53.s7.p1" e1="DrugDDI.d53.s7.e0" e2="DrugDDI.d53.s7.e2" interaction="true"/><pair id="DrugDDI.d53.s7.p2" e1="DrugDDI.d53.s7.e0" e2="DrugDDI.d53.s7.e3" interaction="true"/><pair id="DrugDDI.d53.s7.p3" e1="DrugDDI.d53.s7.e1" e2="DrugDDI.d53.s7.e2" interaction="true"/><pair id="DrugDDI.d53.s7.p4" e1="DrugDDI.d53.s7.e1" e2="DrugDDI.d53.s7.e3" interaction="true"/><pair id="DrugDDI.d53.s7.p5" e1="DrugDDI.d53.s7.e2" e2="DrugDDI.d53.s7.e3" interaction="true"/></sentence><sentence id="DrugDDI.d53.s8" origId="s8" text="The effects celecoxib on the pharmacokinetics and/or pharmacodynamics of glyburide, ketoconazole, methotrexate, phenytoin, tolbutamide, and warfarin have been studied in vivo and clinically important interactions have not been found."><entity id="DrugDDI.d53.s8.e0" origId="s8.p81" charOffset="12-21" type="drug" text="celecoxib"/><entity id="DrugDDI.d53.s8.e1" origId="s8.p85" charOffset="73-82" type="drug" text="glyburide"/><entity id="DrugDDI.d53.s8.e2" origId="s8.p86" charOffset="84-96" type="drug" text="ketoconazole"/><entity id="DrugDDI.d53.s8.e3" origId="s8.p87" charOffset="98-110" type="drug" text="methotrexate"/><entity id="DrugDDI.d53.s8.e4" origId="s8.p88" charOffset="112-121" type="drug" text="phenytoin"/><entity id="DrugDDI.d53.s8.e5" origId="s8.p89" charOffset="123-134" type="drug" text="tolbutamide"/><entity id="DrugDDI.d53.s8.e6" origId="s8.p91" charOffset="140-148" type="drug" text="warfarin"/><pair id="DrugDDI.d53.s8.p0" e1="DrugDDI.d53.s8.e0" e2="DrugDDI.d53.s8.e1" interaction="false"/><pair id="DrugDDI.d53.s8.p1" e1="DrugDDI.d53.s8.e0" e2="DrugDDI.d53.s8.e2" interaction="false"/><pair id="DrugDDI.d53.s8.p2" e1="DrugDDI.d53.s8.e0" e2="DrugDDI.d53.s8.e3" interaction="false"/><pair id="DrugDDI.d53.s8.p3" e1="DrugDDI.d53.s8.e0" e2="DrugDDI.d53.s8.e4" interaction="false"/><pair id="DrugDDI.d53.s8.p4" e1="DrugDDI.d53.s8.e0" e2="DrugDDI.d53.s8.e5" interaction="false"/><pair id="DrugDDI.d53.s8.p5" e1="DrugDDI.d53.s8.e0" e2="DrugDDI.d53.s8.e6" interaction="false"/><pair id="DrugDDI.d53.s8.p6" e1="DrugDDI.d53.s8.e1" e2="DrugDDI.d53.s8.e2" interaction="false"/><pair id="DrugDDI.d53.s8.p7" e1="DrugDDI.d53.s8.e1" e2="DrugDDI.d53.s8.e3" interaction="false"/><pair id="DrugDDI.d53.s8.p8" e1="DrugDDI.d53.s8.e1" e2="DrugDDI.d53.s8.e4" interaction="false"/><pair id="DrugDDI.d53.s8.p9" e1="DrugDDI.d53.s8.e1" e2="DrugDDI.d53.s8.e5" interaction="false"/><pair id="DrugDDI.d53.s8.p10" e1="DrugDDI.d53.s8.e1" e2="DrugDDI.d53.s8.e6" interaction="false"/><pair id="DrugDDI.d53.s8.p11" e1="DrugDDI.d53.s8.e2" e2="DrugDDI.d53.s8.e3" interaction="false"/><pair id="DrugDDI.d53.s8.p12" e1="DrugDDI.d53.s8.e2" e2="DrugDDI.d53.s8.e4" interaction="false"/><pair id="DrugDDI.d53.s8.p13" e1="DrugDDI.d53.s8.e2" e2="DrugDDI.d53.s8.e5" interaction="false"/><pair id="DrugDDI.d53.s8.p14" e1="DrugDDI.d53.s8.e2" e2="DrugDDI.d53.s8.e6" interaction="false"/><pair id="DrugDDI.d53.s8.p15" e1="DrugDDI.d53.s8.e3" e2="DrugDDI.d53.s8.e4" interaction="false"/><pair id="DrugDDI.d53.s8.p16" e1="DrugDDI.d53.s8.e3" e2="DrugDDI.d53.s8.e5" interaction="false"/><pair id="DrugDDI.d53.s8.p17" e1="DrugDDI.d53.s8.e3" e2="DrugDDI.d53.s8.e6" interaction="false"/><pair id="DrugDDI.d53.s8.p18" e1="DrugDDI.d53.s8.e4" e2="DrugDDI.d53.s8.e5" interaction="false"/><pair id="DrugDDI.d53.s8.p19" e1="DrugDDI.d53.s8.e4" e2="DrugDDI.d53.s8.e6" interaction="false"/><pair id="DrugDDI.d53.s8.p20" e1="DrugDDI.d53.s8.e5" e2="DrugDDI.d53.s8.e6" interaction="false"/></sentence><sentence id="DrugDDI.d53.s9" origId="s9" text="ACE inhibitors: Reports suggest that NSAIDs may diminish the antihypertensive effect of Angiotensin Converting Enzyme (ACE) inhibitors."><entity id="DrugDDI.d53.s9.e0" origId="s9.p102" charOffset="0-14" type="drug" text="ACE inhibitors"/><entity id="DrugDDI.d53.s9.e1" origId="s9.p106" charOffset="37-43" type="drug" text="NSAIDs"/><entity id="DrugDDI.d53.s9.e2" origId="s9.p109" charOffset="61-77" type="drug" text="antihypertensive"/><entity id="DrugDDI.d53.s9.e3" origId="s9.p110" charOffset="88-117" type="drug" text="Angiotensin Converting Enzyme"/><pair id="DrugDDI.d53.s9.p0" e1="DrugDDI.d53.s9.e0" e2="DrugDDI.d53.s9.e1" interaction="false"/><pair id="DrugDDI.d53.s9.p1" e1="DrugDDI.d53.s9.e0" e2="DrugDDI.d53.s9.e2" interaction="false"/><pair id="DrugDDI.d53.s9.p2" e1="DrugDDI.d53.s9.e0" e2="DrugDDI.d53.s9.e3" interaction="false"/><pair id="DrugDDI.d53.s9.p3" e1="DrugDDI.d53.s9.e1" e2="DrugDDI.d53.s9.e2" interaction="true"/><pair id="DrugDDI.d53.s9.p4" e1="DrugDDI.d53.s9.e1" e2="DrugDDI.d53.s9.e3" interaction="true"/><pair id="DrugDDI.d53.s9.p5" e1="DrugDDI.d53.s9.e2" e2="DrugDDI.d53.s9.e3" interaction="false"/></sentence><sentence id="DrugDDI.d53.s10" origId="s10" text="This interaction should be given consideration in patients taking CELEBREX concomitantly with ACE-inhibitors."><entity id="DrugDDI.d53.s10.e0" origId="s10.p122" charOffset="66-74" type="drug" text="CELEBREX"/><entity id="DrugDDI.d53.s10.e1" origId="s10.p123" charOffset="94-109" type="drug" text="ACE-inhibitors"/><pair id="DrugDDI.d53.s10.p0" e1="DrugDDI.d53.s10.e0" e2="DrugDDI.d53.s10.e1" interaction="true"/></sentence><sentence id="DrugDDI.d53.s11" origId="s11" text="Furosemide: Clinical studies, as well as post marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients."><entity id="DrugDDI.d53.s11.e0" origId="s11.p124" charOffset="0-10" type="drug" text="Furosemide"/><entity id="DrugDDI.d53.s11.e1" origId="s11.p131" charOffset="86-92" type="drug" text="NSAIDs"/><entity id="DrugDDI.d53.s11.e2" origId="s11.p134" charOffset="108-119" type="drug" text="natriuretic"/><entity id="DrugDDI.d53.s11.e3" origId="s11.p135" charOffset="130-141" type="drug" text="furosemide"/><entity id="DrugDDI.d53.s11.e4" origId="s11.p137" charOffset="145-154" type="drug" text="thiazides"/><pair id="DrugDDI.d53.s11.p0" e1="DrugDDI.d53.s11.e0" e2="DrugDDI.d53.s11.e1" interaction="false"/><pair id="DrugDDI.d53.s11.p1" e1="DrugDDI.d53.s11.e0" e2="DrugDDI.d53.s11.e2" interaction="false"/><pair id="DrugDDI.d53.s11.p2" e1="DrugDDI.d53.s11.e0" e2="DrugDDI.d53.s11.e3" interaction="false"/><pair id="DrugDDI.d53.s11.p3" e1="DrugDDI.d53.s11.e0" e2="DrugDDI.d53.s11.e4" interaction="false"/><pair id="DrugDDI.d53.s11.p4" e1="DrugDDI.d53.s11.e1" e2="DrugDDI.d53.s11.e2" interaction="false"/><pair id="DrugDDI.d53.s11.p5" e1="DrugDDI.d53.s11.e1" e2="DrugDDI.d53.s11.e3" interaction="true"/><pair id="DrugDDI.d53.s11.p6" e1="DrugDDI.d53.s11.e1" e2="DrugDDI.d53.s11.e4" interaction="true"/><pair id="DrugDDI.d53.s11.p7" e1="DrugDDI.d53.s11.e2" e2="DrugDDI.d53.s11.e3" interaction="false"/><pair id="DrugDDI.d53.s11.p8" e1="DrugDDI.d53.s11.e2" e2="DrugDDI.d53.s11.e4" interaction="false"/><pair id="DrugDDI.d53.s11.p9" e1="DrugDDI.d53.s11.e3" e2="DrugDDI.d53.s11.e4" interaction="false"/></sentence><sentence id="DrugDDI.d53.s12" origId="s12" text="This response has been attributed to inhibition of renal prostaglandin synthesis."><entity id="DrugDDI.d53.s12.e0" origId="s12.p144" charOffset="57-70" type="drug" text="prostaglandin"/></sentence><sentence id="DrugDDI.d53.s13" origId="s13" text="Aspirin: CELEBREX can be used with low dose aspirin."><entity id="DrugDDI.d53.s13.e0" origId="s13.p145" charOffset="0-7" type="drug" text="Aspirin"/><entity id="DrugDDI.d53.s13.e1" origId="s13.p147" charOffset="9-17" type="drug" text="CELEBREX"/><entity id="DrugDDI.d53.s13.e2" origId="s13.p151" charOffset="44-51" type="drug" text="aspirin"/><pair id="DrugDDI.d53.s13.p0" e1="DrugDDI.d53.s13.e0" e2="DrugDDI.d53.s13.e1" interaction="false"/><pair id="DrugDDI.d53.s13.p1" e1="DrugDDI.d53.s13.e0" e2="DrugDDI.d53.s13.e2" interaction="false"/><pair id="DrugDDI.d53.s13.p2" e1="DrugDDI.d53.s13.e1" e2="DrugDDI.d53.s13.e2" interaction="false"/></sentence><sentence id="DrugDDI.d53.s14" origId="s14" text="However, concomitant administration of aspirin with CELEBREX may result in an increased rate of GI ulceration or other complications, compared to use of CELEBREX alone."><entity id="DrugDDI.d53.s14.e0" origId="s14.p154" charOffset="39-46" type="drug" text="aspirin"/><entity id="DrugDDI.d53.s14.e1" origId="s14.p155" charOffset="52-60" type="drug" text="CELEBREX"/><entity id="DrugDDI.d53.s14.e2" origId="s14.p165" charOffset="153-161" type="drug" text="CELEBREX"/><pair id="DrugDDI.d53.s14.p0" e1="DrugDDI.d53.s14.e0" e2="DrugDDI.d53.s14.e1" interaction="true"/><pair id="DrugDDI.d53.s14.p1" e1="DrugDDI.d53.s14.e0" e2="DrugDDI.d53.s14.e2" interaction="false"/><pair id="DrugDDI.d53.s14.p2" e1="DrugDDI.d53.s14.e1" e2="DrugDDI.d53.s14.e2" interaction="false"/></sentence><sentence id="DrugDDI.d53.s15" origId="s15" text="Because of its lack of platelet effects, CELEBREX is not a substitute for aspirin for cardiovascular prophylaxis."><entity id="DrugDDI.d53.s15.e0" origId="s15.p168" charOffset="41-49" type="drug" text="CELEBREX"/><entity id="DrugDDI.d53.s15.e1" origId="s15.p171" charOffset="74-81" type="drug" text="aspirin"/><pair id="DrugDDI.d53.s15.p0" e1="DrugDDI.d53.s15.e0" e2="DrugDDI.d53.s15.e1" interaction="false"/></sentence><sentence id="DrugDDI.d53.s16" origId="s16" text="Fluconazole: Concomitant administration of fluconazole at 200 mg QD resulted in a two-fold increase in celecoxib plasma concentration."><entity id="DrugDDI.d53.s16.e0" origId="s16.p173" charOffset="0-11" type="drug" text="Fluconazole"/><entity id="DrugDDI.d53.s16.e1" origId="s16.p176" charOffset="43-54" type="drug" text="fluconazole"/><entity id="DrugDDI.d53.s16.e2" origId="s16.p180" charOffset="103-112" type="drug" text="celecoxib"/><pair id="DrugDDI.d53.s16.p0" e1="DrugDDI.d53.s16.e0" e2="DrugDDI.d53.s16.e1" interaction="false"/><pair id="DrugDDI.d53.s16.p1" e1="DrugDDI.d53.s16.e0" e2="DrugDDI.d53.s16.e2" interaction="false"/><pair id="DrugDDI.d53.s16.p2" e1="DrugDDI.d53.s16.e1" e2="DrugDDI.d53.s16.e2" interaction="true"/></sentence><sentence id="DrugDDI.d53.s17" origId="s17" text="This increase is due to the inhibition of celecoxib metabolism via P450 2C9 by fluconazole (see CLINICAL PHARMACOLOGY - Pharmacokinetics: Metabolism)."><entity id="DrugDDI.d53.s17.e0" origId="s17.p184" charOffset="42-51" type="drug" text="celecoxib"/><entity id="DrugDDI.d53.s17.e1" origId="s17.p185" charOffset="67-71" type="drug" text="P450"/><entity id="DrugDDI.d53.s17.e2" origId="s17.p186" charOffset="79-90" type="drug" text="fluconazole"/><pair id="DrugDDI.d53.s17.p0" e1="DrugDDI.d53.s17.e0" e2="DrugDDI.d53.s17.e1" interaction="false"/><pair id="DrugDDI.d53.s17.p1" e1="DrugDDI.d53.s17.e0" e2="DrugDDI.d53.s17.e2" interaction="true"/><pair id="DrugDDI.d53.s17.p2" e1="DrugDDI.d53.s17.e1" e2="DrugDDI.d53.s17.e2" interaction="false"/></sentence><sentence id="DrugDDI.d53.s18" origId="s18" text="CELEBREX should be introduced at the lowest recommended dose in patients receiving fluconazole."><entity id="DrugDDI.d53.s18.e0" origId="s18.p193" charOffset="0-8" type="drug" text="CELEBREX"/><entity id="DrugDDI.d53.s18.e1" origId="s18.p200" charOffset="83-94" type="drug" text="fluconazole"/><pair id="DrugDDI.d53.s18.p0" e1="DrugDDI.d53.s18.e0" e2="DrugDDI.d53.s18.e1" interaction="true"/></sentence><sentence id="DrugDDI.d53.s19" origId="s19" text="Lithium: In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased approximately 17% in subjects receiving lithium 450 mg BID with CELEBREX 200 mg BID as compared to subjects receiving lithium alone."><entity id="DrugDDI.d53.s19.e0" origId="s19.p201" charOffset="0-7" type="drug" text="Lithium"/><entity id="DrugDDI.d53.s19.e1" origId="s19.p211" charOffset="141-148" type="drug" text="lithium"/><entity id="DrugDDI.d53.s19.e2" origId="s19.p212" charOffset="165-173" type="drug" text="CELEBREX"/><entity id="DrugDDI.d53.s19.e3" origId="s19.p217" charOffset="219-226" type="drug" text="lithium"/><pair id="DrugDDI.d53.s19.p0" e1="DrugDDI.d53.s19.e0" e2="DrugDDI.d53.s19.e1" interaction="false"/><pair id="DrugDDI.d53.s19.p1" e1="DrugDDI.d53.s19.e0" e2="DrugDDI.d53.s19.e2" interaction="false"/><pair id="DrugDDI.d53.s19.p2" e1="DrugDDI.d53.s19.e0" e2="DrugDDI.d53.s19.e3" interaction="false"/><pair id="DrugDDI.d53.s19.p3" e1="DrugDDI.d53.s19.e1" e2="DrugDDI.d53.s19.e2" interaction="true"/><pair id="DrugDDI.d53.s19.p4" e1="DrugDDI.d53.s19.e1" e2="DrugDDI.d53.s19.e3" interaction="false"/><pair id="DrugDDI.d53.s19.p5" e1="DrugDDI.d53.s19.e2" e2="DrugDDI.d53.s19.e3" interaction="false"/></sentence><sentence id="DrugDDI.d53.s20" origId="s20" text="Patients on lithium treatment should be closely monitored when CELEBREX is introduced or withdrawn."><entity id="DrugDDI.d53.s20.e0" origId="s20.p219" charOffset="12-19" type="drug" text="lithium"/><entity id="DrugDDI.d53.s20.e1" origId="s20.p225" charOffset="63-71" type="drug" text="CELEBREX"/><pair id="DrugDDI.d53.s20.p0" e1="DrugDDI.d53.s20.e0" e2="DrugDDI.d53.s20.e1" interaction="true"/></sentence><sentence id="DrugDDI.d53.s21" origId="s21" text="Methotrexate: In an interaction study of rheumatoid arthritis patients taking methotrexate, CELEBREX did not have a significant effect on the pharmacokinetics of methotrexate."><entity id="DrugDDI.d53.s21.e0" origId="s21.p230" charOffset="0-12" type="drug" text="Methotrexate"/><entity id="DrugDDI.d53.s21.e1" origId="s21.p235" charOffset="78-90" type="drug" text="methotrexate"/><entity id="DrugDDI.d53.s21.e2" origId="s21.p236" charOffset="92-100" type="drug" text="CELEBREX"/><entity id="DrugDDI.d53.s21.e3" origId="s21.p242" charOffset="162-174" type="drug" text="methotrexate"/><pair id="DrugDDI.d53.s21.p0" e1="DrugDDI.d53.s21.e0" e2="DrugDDI.d53.s21.e1" interaction="false"/><pair id="DrugDDI.d53.s21.p1" e1="DrugDDI.d53.s21.e0" e2="DrugDDI.d53.s21.e2" interaction="false"/><pair id="DrugDDI.d53.s21.p2" e1="DrugDDI.d53.s21.e0" e2="DrugDDI.d53.s21.e3" interaction="false"/><pair id="DrugDDI.d53.s21.p3" e1="DrugDDI.d53.s21.e1" e2="DrugDDI.d53.s21.e2" interaction="false"/><pair id="DrugDDI.d53.s21.p4" e1="DrugDDI.d53.s21.e1" e2="DrugDDI.d53.s21.e3" interaction="false"/><pair id="DrugDDI.d53.s21.p5" e1="DrugDDI.d53.s21.e2" e2="DrugDDI.d53.s21.e3" interaction="false"/></sentence><sentence id="DrugDDI.d53.s22" origId="s22" text="Warfarin: The effect of celecoxib on the anti-coagulant effect of warfarin was studied in a group of healthy subjects receiving daily doses of 2-5 mg of warfarin."><entity id="DrugDDI.d53.s22.e0" origId="s22.p243" charOffset="0-8" type="drug" text="Warfarin"/><entity id="DrugDDI.d53.s22.e1" origId="s22.p246" charOffset="24-33" type="drug" text="celecoxib"/><entity id="DrugDDI.d53.s22.e2" origId="s22.p248" charOffset="66-74" type="drug" text="warfarin"/><entity id="DrugDDI.d53.s22.e3" origId="s22.p256" charOffset="153-161" type="drug" text="warfarin"/><pair id="DrugDDI.d53.s22.p0" e1="DrugDDI.d53.s22.e0" e2="DrugDDI.d53.s22.e1" interaction="false"/><pair id="DrugDDI.d53.s22.p1" e1="DrugDDI.d53.s22.e0" e2="DrugDDI.d53.s22.e2" interaction="false"/><pair id="DrugDDI.d53.s22.p2" e1="DrugDDI.d53.s22.e0" e2="DrugDDI.d53.s22.e3" interaction="false"/><pair id="DrugDDI.d53.s22.p3" e1="DrugDDI.d53.s22.e1" e2="DrugDDI.d53.s22.e2" interaction="false"/><pair id="DrugDDI.d53.s22.p4" e1="DrugDDI.d53.s22.e1" e2="DrugDDI.d53.s22.e3" interaction="false"/><pair id="DrugDDI.d53.s22.p5" e1="DrugDDI.d53.s22.e2" e2="DrugDDI.d53.s22.e3" interaction="false"/></sentence><sentence id="DrugDDI.d53.s23" origId="s23" text="In these subjects, celecoxib did not alter the anticoagulant effect of warfarin as determined by prothrombin time."><entity id="DrugDDI.d53.s23.e0" origId="s23.p258" charOffset="19-28" type="drug" text="celecoxib"/><entity id="DrugDDI.d53.s23.e1" origId="s23.p263" charOffset="71-79" type="drug" text="warfarin"/><pair id="DrugDDI.d53.s23.p0" e1="DrugDDI.d53.s23.e0" e2="DrugDDI.d53.s23.e1" interaction="false"/></sentence><sentence id="DrugDDI.d53.s24" origId="s24" text="However, caution should be used when administering CELEBREX with warfarin since these patients are at increased risk of bleeding complications."><entity id="DrugDDI.d53.s24.e0" origId="s24.p273" charOffset="51-59" type="drug" text="CELEBREX"/><entity id="DrugDDI.d53.s24.e1" origId="s24.p274" charOffset="65-73" type="drug" text="warfarin"/><pair id="DrugDDI.d53.s24.p0" e1="DrugDDI.d53.s24.e0" e2="DrugDDI.d53.s24.e1" interaction="true"/></sentence></document>